Project Grant R41EB036916
Award Date
9/15/24
Completion Date
8/31/26
Dollars Obligated
$307K
Federal Agency
National Institute of Biomedical Imaging and Bioenginering
Federal Grant Program
93.286
Assistance Type
Project Grant
Place of Performance
Mississippi, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $246,000.00 to The Trustees of Princeton University to investigate the brain mechanisms underlying the therapeutic potential of psilocybin. The research aims to: 1) examine the accelerated acquisition of motivated behavior and task performance after psilocybin administration, and 2) identify the cellular and brain-wide substrates driving...
This Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the federal Research and Training in Complementary and Integrative Health program (CFDA 93.213), will fund a feasibility clinical trial to develop and evaluate a Psilocybin-Assisted Cognitive Behavioral Therapy (PA-CBT) protocol for treating major depressive disorder. The $236,250 award, granted on December 17, 2024, supports a 3-year study to refine and optimize the PA-CBT approach, and...
This $1,255,890 Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants (CFDA 93.242) program, supports research at Cornell University to investigate the role of cortical GABAergic interneurons in the effects of the psychedelic drug psilocybin. The key objectives are to: 1) use cell type-specific electrophysiology to measure how the three major subtypes of GABAergic interneurons in the mouse medial frontal cortex respond to psilocybin...
The National Institute of Mental Health (NIMH) awarded a $679,118 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the University of California, Santa Cruz (UCSC) to study the cellular and circuit mechanisms underlying the long-lasting therapeutic effects of the psychedelic drug psilocybin in the stressed brain. The project aims to determine how psilocybin affects synaptic plasticity, cortical functional networks, and the representation of behavioral variables in the stressed...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $6,489,450.00 to New York University to evaluate psilocybin as an adjunctive treatment for opioid use disorder (OUD) in methadone-maintained patients who continue to use illicit opioids. The study will recruit 240 participants from opioid treatment programs in New York and New Mexico, and will provide psilocybin treatment implemented as...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding research at the University of Oregon to investigate the polypharmacology and psychoplastogenic effects of psychedelic drugs using the C. elegans model organism. The overarching goal is to determine how representative psychedelic compounds, which primarily activate serotonin receptors, influence behavior and neuroplasticity in this invertebrate...
This federal Project Grant award for $708,511 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund a mechanistic trial to elucidate the effects of psilocybin on neural activity in individuals with alcohol use disorder (AUD). The study aims to evaluate the impacts of high-dose versus low-dose psilocybin on AUD patients' neural response to negative affective stimuli and alcohol cues, as well as subsequent drinking...
The National Institute on Drug Abuse (NIDA) awarded a $306,528 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Addinex Technologies, Inc. The grant will fund the development of a medication adherence and monitoring system to support decentralized clinical trials for substance use disorder (SUD). The project aims to adapt Addinex's existing medication management system to provide researchers running SUD clinical trials with a tool for at-home dispensing that...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 - Drug Use and Addiction Research Programs, is supporting the development of a bioabsorbable, subcutaneous, extended-release buprenorphine implant for the treatment of opioid use disorder (OUD). The $2,932,500 award to The Drug Delivery Company, LLC will fund the development of this 6-month buprenorphine implant, building upon the company's prior success with a 6-month bioabsorbable...
The National Institute on Drug Abuse (NIDA) awarded a $386,452 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant supports the development of a rapid fingerstick diagnostic test for opioid and stimulant use disorders. This project aims to address the escalating public health crisis of opioid and stimulant overdose deaths in the United States, which reached over 107,000 in...